Valuation: OLIPASS Corporation

Market Cap 26.53B 18.23M 16M 14.9M 13.71M 25.69M 1.74B 26.13M 177M 69.2M 864M 68.45M 66.98M 2.98B P/E 2021
-10.8x
P/E 2022 -7.66x
Enterprise Value 20.34B 13.98M 12.27M 11.42M 10.51M 19.69M 1.34B 20.03M 136M 53.04M 662M 52.47M 51.34M 2.29B EV / Sales 2021
295x
EV / Sales 2022 79x
Free-Float
48.85%
Yield 2021 *
-
Yield 2022 -
3 years 1,568
Extreme 1568
34,500
5 years 1,568
Extreme 1568
158,000
10 years 1,568
Extreme 1568
240,666.67
Manager TitleAgeSince
Chief Executive Officer 54 22/05/2025
Corporate Officer/Principal 34 28/11/2024
Comptroller/Controller/Auditor 67 31/03/2025
Director TitleAgeSince
Director/Board Member 54 28/11/2024
Director/Board Member 34 28/11/2024
Director/Board Member 66 -
Change 5-day change 1-year change 3-year change Capi.($)
-13.92%-.--%-.--%-90.11% 9.26M
-0.05%+1.64%+49.84%+68.67% 55.01B
-1.32%-2.71%+34.27%+77.57% 54.24B
+1.49%+0.13%-18.03%-13.94% 23.38B
-0.57%-4.13%+2.34%+387.73% 22.57B
+2.07%+1.39%+17.20%-10.70% 20.19B
-0.71%-0.58%+29.52%-31.83% 17.86B
-2.14%-3.75%+26.23%+558.64% 15.5B
-6.69%-5.11%+169.13%+304.89% 14.2B
+1.25%+0.69%+27.30%+184.69% 14.2B
Average -2.36%-5.18%+33.78%+143.56% 23.72B
Weighted average by Cap. -0.87%-0.52%+35.01%+131.71%

Financials

2021 2022
Net sales 852M 585K 514K 478K 440K 825K 55.93M 839K 5.68M 2.22M 27.74M 2.2M 2.15M 95.83M 2.3B 1.58M 1.38M 1.29M 1.19M 2.22M 151M 2.26M 15.3M 5.99M 74.77M 5.92M 5.8M 258M
Net income -25.13B -17.27M -15.16M -14.12M -12.98M -24.34M -1.65B -24.76M -167M -65.56M -818M -64.85M -63.45M -2.83B -24.17B -16.61M -14.58M -13.57M -12.49M -23.4M -1.59B -23.81M -161M -63.03M -787M -62.36M -61.01M -2.72B
Net Debt -18.29B -12.57M -11.03M -10.27M -9.45M -17.71M -1.2B -18.02M -122M -47.71M -596M -47.19M -46.17M -2.06B -6.2B -4.26M -3.74M -3.48M -3.2M -6M -407M -6.1M -41.28M -16.16M -202M -15.98M -15.64M -697M
Logo OLIPASS Corporation
OliPass Corp is a Korea-based company principally engaged in the research and development of biopharmaceuticals. The Company is mainly engaged in the development of non-opioid analgesics, amyotrophic lateral sclerosis (ALS) treatments, therapies for age-related macular degeneration, and diabetic retinopathy. In addition, the Company researches, develops and sells functional cosmetics through artificial gene platform technology.
Employees
78
  1. Stock Market
  2. Stocks
  3. A244460 Stock